Mucopolysaccharidosis Treatment Market to Record a CAGR of 5.10%, ArmaGen Inc., Sangamo Therapeutics and Hamilton Storage Technologies Among Key Vendors – Market.us

Pune, Maharashtra, India, September 12 2022 (Wiredrelease) Prudour Pvt. Ltd –:Mucopolysaccharidosis (MPS) is a rare, progressive genetic disorder that causes severe damage to the body’s tissues and organs. There is no cure for MPS, but treatment can help manage the symptoms and slow the progression of the disease. Early diagnosis and treatment are vital to improve the quality of life for people with MPS. This article will provide an overview of MPS and its treatment.

The Worldwide Mucopolysaccharidosis Treatment Market is estimated to be worth around USD 2.340 Bn in 2022 and this market is projected to grow at a robust CAGR of 5.10% between 2022 and 2029, reaching a valuation of USD 3.40 Bn by 2029.

Mucopolysaccharidosis (MPS) is a rare disease that affects children. There is no cure for MPS, but treatments are available to manage the symptoms and slow the progression of the disease. The global mucopolysaccharidosis treatment market is expected to grow significantly during the forecast period (2022-2032). This growth is primarily due to the increasing prevalence of MPS, availability of new treatments, and government initiatives to raise awareness about MPS.

Mucopolysaccharidosis (MPS) Treatment Market: Restraints

High cost of therapeutics coupled with poor diagnosis are expected to hinder growth of the global mucopolysaccharidosis (MPS) treatment market during the forecast period. Vimizin (elosulfase-alfa) is a treatment for MPS IV (Morquio Syndrome). It was launched in the market at a cost of US$ 380,000 per year. Patients in emerging economies like India can’t afford this treatment because of the high price.

Another key limiting factor is the delay associated with the diagnosis of mucopolysaccharidosis. For instance, according to the study published in 2018, in the Orphanet Journal of Rare Diseases, there is a failure in diagnosis of the two ultra-orphan diseases of mucopolysaccharidosis type I and mucopolysaccharidosis type III.

For Right Perspective & Competitive Insights on Mucopolysaccharidosis Treatment Market, Request for a Sample PDF: https://market.us/report/mucopolysaccharidosis-treatment-market/request-sample/

Key Market Players included in the report:

BioMarin Pharmaceutical Inc.
Genzyme
a Sanofi Company
ArmaGen Inc.
Sangamo Therapeutics
Hamilton Storage Technologies

Key Market Segments

Type

Enzyme Replacement Therapy
Stem Cell Therapy
Others

Application

Hospitals
Clinics
Specialty Care Unit
Others

Regional Segmentation:

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

To turn massive challenges into meaningful change, Make an Inquiry of the report@ https://market.us/report/mucopolysaccharidosis-treatment-market/#inquiry  

Who will all get benefits from Global Mucopolysaccharidosis Treatment market research report?

– Product managers, Mucopolysaccharidosis Treatment industry administrator, chief administrative officers of the industries.

– Scientists, Mucopolysaccharidosis Treatment investigators, research analysts, and laboratory expertise.

– Universities, students, interns, professors and various other academic organization interested in Mucopolysaccharidosis Treatment market.

– Writer, journalists, editors, reporter and webmasters get to know about Mucopolysaccharidosis Treatment.

– Private/governmental institutes, project managers associate in Mucopolysaccharidosis Treatment industry.

– Current or forthcoming Mucopolysaccharidosis Treatment market players.

Frequently Asked Questions

What are the growth estimates for the global mucopolysaccharidosis (MPS) treatment market till 2032?

What will be the compound annual growth rate (CAGR) for the global mucopolysaccharidosis (MPS) treatment market during the forecast period?

What is the current mucopolysaccharidosis treatment market valuation?

What is the mucopolysaccharidosis treatment market demand outlook?

At what rate did the mucopolysaccharidosis treatment market grow between 2015 and 2021?

What are the key trends shaping the mucopolysaccharidosis treatment market?

Who are the leading players in mucopolysaccharidosis treatment market?

What are the key factors hampering growth of the market?

MORE RELATED REPORTS FROM OUR DATABASE :

Global Chronic Pain Treatment Market Size To Bolster Over 2022-2031

Global Gene Therapy for Mucopolysaccharidosis Market Recent Developments and SWOT Analysis 2031

Global Mucopolysaccharidosis II Market To Display Lucrative Growth Trends Over 2022-2031

Global Actinic Keratosis Treatment Market Promising Growth Opportunities and Forecast by 2031

Global Glioblastoma Multiforme Treatment Market 2022 is Booming Worldwide Business Forecast by 2031

Media Contact

Company Name: Market.us (Powered By Prudour Pvt. Ltd.)

Global Business Development Teams – Market.us

Email: inquiry@market.us

Phone: +1 718 618 4351

Address: 420 Lexington Avenue, Suite 300 New York City, NY 10170, United States

Connect with us at LinkedIn | Facebook | Twitter

This content has been published by Prudour Pvt. Ltd company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at contact@wiredrelease.com.